Endocrinol Metab.  2024 Aug;39(4):539-551. 10.3803/EnM.2024.1963.

Effects of Endocrine-Disrupting Chemicals on Bone Health

• Park SY
• Kong SH
• Kim KJ
• Ahn SH
• Hong N
• Ha J
• Lee S
• Choi HS
• Baek KH
• Kim JE
• Kim SW
• on Behalf of Metabolic Bone Disease Study Group of Korean Endocrine Society

• KMID: 2558936
• DOI: http://doi.org/10.3803/EnM.2024.1963

Abstract

This comprehensive review critically examines the detrimental impacts of endocrine-disrupting chemicals (EDCs) on bone health, with a specific focus on substances such as bisphenol A (BPA), per- and polyfluoroalkyl substances (PFASs), phthalates, and dioxins. These EDCs, by interfering with the endocrine system’s normal functioning, pose a significant risk to bone metabolism, potentially leading to a heightened susceptibility to bone-related disorders and diseases. Notably, BPA has been shown to inhibit the differentiation of osteoblasts and promote the apoptosis of osteoblasts, which results in altered bone turnover status. PFASs, known for their environmental persistence and ability to bioaccumulate in the human body, have been linked to an increased osteoporosis risk. Similarly, phthalates, which are widely used in the production of plastics, have been associated with adverse bone health outcomes, showing an inverse relationship between phthalate exposure and bone mineral density. Dioxins present a more complex picture, with research findings suggesting both potential benefits and adverse effects on bone structure and density, depending on factors such as the timing and level of exposure. This review underscores the urgent need for further research to better understand the specific pathways through which EDCs affect bone health and to develop targeted strategies for mitigating their potentially harmful impacts.

Keyword

Osteoporosis; Endocrine disruptors; Bone density

Figure

• 

  Fig. 1. Pathogenic effects of endocrine-disrupting chemicals (EDCs) on bone health within the bone marrow microenvironment. BPA, bisphenol A; PFAS, per- and polyfluoroalkyl substance; Ca, calcium.

Reference

1. Diamanti-Kandarakis E, Bourguignon JP, Giudice LC, Hauser R, Prins GS, Soto AM, et al. Endocrine-disrupting chemicals: an Endocrine Society scientific statement. Endocr Rev. 2009; 30:293–342.

2. Tabb MM, Blumberg B. New modes of action for endocrine-disrupting chemicals. Mol Endocrinol. 2006; 20:475–82.

3. Hoffman K, Hammel SC, Phillips AL, Lorenzo AM, Chen A, Calafat AM, et al. Biomarkers of exposure to SVOCs in children and their demographic associations: the TESIE Study. Environ Int. 2018; 119:26–36.

4. Groh KJ, Backhaus T, Carney-Almroth B, Geueke B, Inostroza PA, Lennquist A, et al. Overview of known plastic packaging-associated chemicals and their hazards. Sci Total Environ. 2019; 651(Pt 2):3253–68.

5. Biasiotto G, Zanella I, Masserdotti A, Pedrazzani R, Papa M, Caimi L, et al. Municipal wastewater affects adipose deposition in male mice and increases 3T3-L1 cell differentiation. Toxicol Appl Pharmacol. 2016; 297:32–40.

6. Barber LB, Vajda AM, Douville C, Norris DO, Writer JH. Fish endocrine disruption responses to a major wastewater treatment facility upgrade. Environ Sci Technol. 2012; 46:2121–31.

7. Ding D, Xu L, Fang H, Hong H, Perkins R, Harris S, et al. The EDKB: an established knowledge base for endocrine disrupting chemicals. BMC Bioinformatics. 2010; 11 Suppl 6:S5.

8. Schantz SL, Widholm JJ. Cognitive effects of endocrine-disrupting chemicals in animals. Environ Health Perspect. 2001; 109:1197–206.

9. La Merrill MA, Vandenberg LN, Smith MT, Goodson W, Browne P, Patisaul HB, et al. Consensus on the key characteristics of endocrine-disrupting chemicals as a basis for hazard identification. Nat Rev Endocrinol. 2020; 16:45–57.

10. Agas D, Sabbieti MG, Marchetti L. Endocrine disruptors and bone metabolism. Arch Toxicol. 2013; 87:735–51.

11. Brunetti G, D’Amelio P, Wasniewska M, Mori G, Faienza MF. Editorial: bone: endocrine target and organ. Front Endocrinol (Lausanne). 2017; 8:354.

12. Lee HR, Jeung EB, Cho MH, Kim TH, Leung PC, Choi KC. Molecular mechanism(s) of endocrine-disrupting chemicals and their potent oestrogenicity in diverse cells and tissues that express oestrogen receptors. J Cell Mol Med. 2013; 17:1–11.

13. Agas D, Lacava G, Sabbieti MG. Bone and bone marrow disruption by endocrine-active substances. J Cell Physiol. 2018; 234:192–213.

14. Turan S. Endocrine disrupting chemicals and bone. Best Pract Res Clin Endocrinol Metab. 2021; 35:101495.

15. Yaglova NV, Yaglov VV. Endocrine disruptors as a new etiologic factor of bone tissue diseases (review). Sovrem Tekhnologii Med. 2021; 13:84–94.

16. Chin KY, Pang KL, Mark-Lee WF. A review on the effects of bisphenol A and its derivatives on skeletal health. Int J Med Sci. 2018; 15:1043–50.

17. Almeida M, Laurent MR, Dubois V, Claessens F, O’Brien CA, Bouillon R, et al. Estrogens and androgens in skeletal physiology and pathophysiology. Physiol Rev. 2017; 97:135–87.

18. Emmanuelle NE, Marie-Cecile V, Florence T, Jean-Francois A, Francoise L, Coralie F, et al. Critical role of estrogens on bone homeostasis in both male and female: from physiology to medical implications. Int J Mol Sci. 2021; 22:1568.

19. Khosla S, Oursler MJ, Monroe DG. Estrogen and the skeleton. Trends Endocrinol Metab. 2012; 23:576–81.

20. Kopras E, Potluri V, Bermudez ML, Williams K, Belcher S, Kasper S. Actions of endocrine-disrupting chemicals on stem/progenitor cells during development and disease. Endocr Relat Cancer. 2014; 21:T1–12.

21. Iwobi N, Sparks NR. Endocrine disruptor-induced bone damage due to hormone dysregulation: a review. Int J Mol Sci. 2023; 24:8263.

22. Eriksen EF. Cellular mechanisms of bone remodeling. Rev Endocr Metab Disord. 2010; 11:219–27.

23. Kim JM, Lin C, Stavre Z, Greenblatt MB, Shim JH. Osteoblast-osteoclast communication and bone homeostasis. Cells. 2020; 9:2073.

24. Bateman ME, Strong AL, McLachlan JA, Burow ME, Bunnell BA. The effects of endocrine disruptors on adipogenesis and osteogenesis in mesenchymal stem cells: a review. Front Endocrinol (Lausanne). 2017; 7:171.

25. Detsch R, Boccaccini AR. The role of osteoclasts in bone tissue engineering. J Tissue Eng Regen Med. 2015; 9:1133–49.

26. Tai V, Leung W, Grey A, Reid IR, Bolland MJ. Calcium intake and bone mineral density: systematic review and meta-analysis. BMJ. 2015; 351:h4183.

27. Vannucci L, Fossi C, Quattrini S, Guasti L, Pampaloni B, Gronchi G, et al. Calcium intake in bone health: a focus on calcium-rich mineral waters. Nutrients. 2018; 10:1930.

28. Veldurthy V, Wei R, Oz L, Dhawan P, Jeon YH, Christakos S. Vitamin D, calcium homeostasis and aging. Bone Res. 2016; 4:16041.

29. Babic Leko M, Pleic N, Gunjaca I, Zemunik T. Environmental factors that affect parathyroid hormone and calcitonin levels. Int J Mol Sci. 2021; 23:44.

30. Zhao E, Xu H, Wang L, Kryczek I, Wu K, Hu Y, et al. Bone marrow and the control of immunity. Cell Mol Immunol. 2012; 9:11–9.

31. Adamopoulos IE. Inflammation in bone physiology and pathology. Curr Opin Rheumatol. 2018; 30:59–64.

32. Peng X, Zhou X, Yin Y, Luo B, Liu Y, Yang C. Inflammatory microenvironment accelerates bone marrow mesenchymal stem cell aging. Front Bioeng Biotechnol. 2022; 10:870324.

33. Terkawi MA, Matsumae G, Shimizu T, Takahashi D, Kadoya K, Iwasaki N. Interplay between inflammation and pathological bone resorption: insights into recent mechanisms and pathways in related diseases for future perspectives. Int J Mol Sci. 2022; 23:1786.

34. Bahadar H, Abdollahi M, Maqbool F, Baeeri M, Niaz K. Mechanistic overview of immune modulatory effects of environmental toxicants. Inflamm Allergy Drug Targets. 2015; 13:382–6.

35. Bansal A, Henao-Mejia J, Simmons RA. Immune system: an emerging player in mediating effects of endocrine disruptors on metabolic health. Endocrinology. 2018; 159:32–45.

36. Nowak K, Jablonska E, Ratajczak-Wrona W. Immunomodulatory effects of synthetic endocrine disrupting chemicals on the development and functions of human immune cells. Environ Int. 2019; 125:350–64.

37. Wang X, Nag R, Brunton NP, Siddique MA, Harrison SM, Monahan FJ, et al. Human health risk assessment of bisphenol A (BPA) through meat products. Environ Res. 2022; 213:113734.

38. Chen WY, Shen YP, Chen SC. Assessing bisphenol A (BPA) exposure risk from long-term dietary intakes in Taiwan. Sci Total Environ. 2016; 543(Pt A):140–6.

39. Genuis SJ, Beesoon S, Birkholz D, Lobo RA. Human excretion of bisphenol A: blood, urine, and sweat (BUS) study. J Environ Public Health. 2012; 2012:185731.

40. Thayer KA, Doerge DR, Hunt D, Schurman SH, Twaddle NC, Churchwell MI, et al. Pharmacokinetics of bisphenol A in humans following a single oral administration. Environ Int. 2015; 83:107–15.

41. Fernandez MF, Arrebola JP, Taoufiki J, Navalon A, Ballesteros O, Pulgar R, et al. Bisphenol-A and chlorinated derivatives in adipose tissue of women. Reprod Toxicol. 2007; 24:259–64.

42. Ma Y, Liu H, Wu J, Yuan L, Wang Y, Du X, et al. The adverse health effects of bisphenol A and related toxicity mechanisms. Environ Res. 2019; 176:108575.

43. Wozniak AL, Bulayeva NN, Watson CS. Xenoestrogens at picomolar to nanomolar concentrations trigger membrane estrogen receptor-alpha-mediated Ca2+ fluxes and prolactin release in GH3/B6 pituitary tumor cells. Environ Health Perspect. 2005; 113:431–9.

44. Bolli A, Galluzzo P, Ascenzi P, Del Pozzo G, Manco I, Vietri MT, et al. Laccase treatment impairs bisphenol A-induced cancer cell proliferation affecting estrogen receptor alpha-dependent rapid signals. IUBMB Life. 2008; 60:843–52.

45. Suzuki N, Hattori A. Bisphenol A suppresses osteoclastic and osteoblastic activities in the cultured scales of goldfish. Life Sci. 2003; 73:2237–47.

46. Akingbemi BT, Sottas CM, Koulova AI, Klinefelter GR, Hardy MP. Inhibition of testicular steroidogenesis by the xenoestrogen bisphenol A is associated with reduced pituitary luteinizing hormone secretion and decreased steroidogenic enzyme gene expression in rat Leydig cells. Endocrinology. 2004; 145:592–603.

47. Nakamura D, Yanagiba Y, Duan Z, Ito Y, Okamura A, Asaeda N, et al. Bisphenol A may cause testosterone reduction by adversely affecting both testis and pituitary systems similar to estradiol. Toxicol Lett. 2010; 194:16–25.

48. Nikula H, Talonpoika T, Kaleva M, Toppari J. Inhibition of hCG-stimulated steroidogenesis in cultured mouse Leydig tumor cells by bisphenol A and octylphenols. Toxicol Appl Pharmacol. 1999; 157:166–73.

49. Kim JY, Han EH, Kim HG, Oh KN, Kim SK, Lee KY, et al. Bisphenol A-inducedaromatase activation is mediated by cyclooxygenase-2 up-regulation in rat testicular Leydig cells. Toxicol Lett. 2010; 193:200–8.

50. Lejonklou MH, Christiansen S, Orberg J, Shen L, Larsson S, Boberg J, et al. Low-dose developmental exposure to bisphenol A alters the femoral bone geometry in Wistar rats. Chemosphere. 2016; 164:339–46.

51. Kim JC, Shin HC, Cha SW, Koh WS, Chung MK, Han SS. Evaluation of developmental toxicity in rats exposed to the environmental estrogen bisphenol A during pregnancy. Life Sci. 2001; 69:2611–25.

52. Kim S, An BS, Yang H, Jeung EB. Effects of octylphenol and bisphenol A on the expression of calcium transport genes in the mouse duodenum and kidney during pregnancy. Toxicology. 2013; 303:99–106.

53. Otsuka H, Sugimoto M, Ikeda S, Kume S. Effects of bisphenol A administration to pregnant mice on serum Ca and intestinal Ca absorption. Anim Sci J. 2012; 83:232–7.

54. Kim DH, Oh CH, Hwang YC, Jeong IK, Ahn KJ, Chung HY, et al. Serum bisphenol a concentration in postmenopausal women with osteoporosis. J Bone Metab. 2012; 19:87–93.

55. Zhao HY, Bi YF, Ma LY, Zhao L, Wang TG, Zhang LZ, et al. The effects of bisphenol A (BPA) exposure on fat mass and serum leptin concentrations have no impact on bone mineral densities in non-obese premenopausal women. Clin Biochem. 2012; 45:1602–6.

56. Yang YJ, Hong YC, Oh SY, Park MS, Kim H, Leem JH, et al. Bisphenol A exposure is associated with oxidative stress and inflammation in postmenopausal women. Environ Res. 2009; 109:797–801.

57. Savastano S, Tarantino G, D’Esposito V, Passaretti F, Cabaro S, Liotti A, et al. Bisphenol-A plasma levels are related to inflammatory markers, visceral obesity and insulin-resistance: a cross-sectional study on adult male population. J Transl Med. 2015; 13:169.

58. Wang Z, Cousins IT, Scheringer M, Buck RC, Hungerbuhler K. Global emission inventories for C4-C14 perfluoroalkyl carboxylic acid (PFCA) homologues from 1951 to 2030, part I: production and emissions from quantifiable sources. Environ Int. 2014; 70:62–75.

59. Kirk AB, DeStefano A, Martin A, Kirk KC, Martin CF. A new interpretation of relative importance on an analysis of per and polyfluorinated alkyl substances (PFAS) exposures on bone mineral density. Int J Environ Res Public Health. 2023; 20:4539.

60. Fan S, Wu Y, Bloom MS, Lv J, Chen L, Wang W, et al. Associations of per- and polyfluoroalkyl substances and their alternatives with bone mineral density levels and osteoporosis prevalence: a community-based population study in Guangzhou, Southern China. Sci Total Environ. 2023; 862:160617.

61. Banjabi AA, Li AJ, Kumosani TA, Yousef JM, Kannan K. Serum concentrations of perfluoroalkyl substances and their association with osteoporosis in a population in Jeddah, Saudi Arabia. Environ Res. 2020; 187:109676.

62. Hu Y, Liu G, Rood J, Liang L, Bray GA, de Jonge L, et al. Perfluoroalkyl substances and changes in bone mineral density: a prospective analysis in the POUNDS-LOST study. Environ Res. 2019; 179(Pt A):108775.

63. Khalil N, Ebert JR, Honda M, Lee M, Nahhas RW, Koskela A, et al. Perfluoroalkyl substances, bone density, and cardio-metabolic risk factors in obese 8-12 year old children: a pilot study. Environ Res. 2018; 160:314–21.

64. Yamamoto J, Yamane T, Oishi Y, Kobayashi-Hattori K. Perfluorooctanoic acid binds to peroxisome proliferator-activated receptor γ and promotes adipocyte differentiation in 3T3-L1 adipocytes. Biosci Biotechnol Biochem. 2015; 79:636–9.

65. Greenhill C. Endocrine disruptors: PFASs, sex hormones and asthma. Nat Rev Endocrinol. 2017; 13:377.

66. Kim MJ, Moon S, Oh BC, Jung D, Ji K, Choi K, et al. Association between perfluoroalkyl substances exposure and thyroid function in adults: a meta-analysis. PLoS One. 2018; 13:e0197244.

67. Venken K, Callewaert F, Boonen S, Vanderschueren D. Sex hormones, their receptors and bone health. Osteoporos Int. 2008; 19:1517–25.

68. Bassett JH, Williams GR. Role of thyroid hormones in skeletal development and bone maintenance. Endocr Rev. 2016; 37:135–87.

69. Koskela A, Koponen J, Lehenkari P, Viluksela M, Korkalainen M, Tuukkanen J. Perfluoroalkyl substances in human bone: concentrations in bones and effects on bone cell differentiation. Sci Rep. 2017; 7:6841.

70. Shi X, Zhou B. The role of Nrf2 and MAPK pathways in PFOS-induced oxidative stress in zebrafish embryos. Toxicol Sci. 2010; 115:391–400.

71. Zhang B, He Y, Huang Y, Hong D, Yao Y, Wang L, et al. Novel and legacy poly- and perfluoroalkyl substances (PFASs) in indoor dust from urban, industrial, and e-waste dismantling areas: the emergence of PFAS alternatives in China. Environ Pollut. 2020; 263(Pt A):114461.

72. Sunderland EM, Hu XC, Dassuncao C, Tokranov AK, Wagner CC, Allen JG. A review of the pathways of human exposure to poly- and perfluoroalkyl substances (PFASs) and present understanding of health effects. J Expo Sci Environ Epidemiol. 2019; 29:131–47.

73. Cong J, Chu C, Li QQ, Zhou Y, Min Qian Z, Dee Geiger S, et al. Associations of perfluorooctane sulfonate alternatives and serum lipids in Chinese adults. Environ Int. 2021; 155:106596.

74. Sheng N, Wang J, Guo Y, Wang J, Dai J. Interactions of perfluorooctanesulfonate and 6:2 chlorinated polyfluorinated ether sulfonate with human serum albumin: a comparative study. Chem Res Toxicol. 2020; 33:1478–86.

75. Zheng P, Liu Y, An Q, Yang X, Yin S, Ma LQ, et al. Prenatal and postnatal exposure to emerging and legacy per-/polyfluoroalkyl substances: levels and transfer in maternal serum, cord serum, and breast milk. Sci Total Environ. 2022; 812:152446.

76. Sheng N, Zhou X, Zheng F, Pan Y, Guo X, Guo Y, et al. Comparative hepatotoxicity of 6:2 fluorotelomer carboxylic acid and 6:2 fluorotelomer sulfonic acid, two fluorinated alternatives to long-chain perfluoroalkyl acids, on adult male mice. Arch Toxicol. 2017; 91:2909–19.

77. Wang Y, Qian H. Phthalates and their impacts on human health. Healthcare (Basel). 2021; 9:603.

78. Basso CG, de Araujo-Ramos AT, Martino-Andrade AJ. Exposure to phthalates and female reproductive health: a literature review. Reprod Toxicol. 2022; 109:61–79.

79. Filardi T, Panimolle F, Lenzi A, Morano S. Bisphenol A and phthalates in diet: an emerging link with pregnancy complications. Nutrients. 2020; 12:525.

80. Basak S, Das MK, Duttaroy AK. Plastics derived endocrinedisrupting compounds and their effects on early development. Birth Defects Res. 2020; 112:1308–25.

81. Mallozzi M, Bordi G, Garo C, Caserta D. The effect of maternal exposure to endocrine disrupting chemicals on fetal and neonatal development: a review on the major concerns. Birth Defects Res C Embryo Today. 2016; 108:224–42.

82. Heilmann NZ, Reeves KW, Hankinson SE. Phthalates and bone mineral density: a systematic review. Environ Health. 2022; 21:108.

83. DeFlorio-Barker SA, Turyk ME. Associations between bone mineral density and urinary phthalate metabolites among post-menopausal women: a cross-sectional study of NHANES data 2005-2010. Int J Environ Health Res. 2016; 26:326–45.

84. Reeves KW, Vieyra G, Grimes NP, Meliker J, Jackson RD, Wactawski-Wende J, et al. Urinary phthalate biomarkers and bone mineral density in postmenopausal women. J Clin Endocrinol Metab. 2021; 106:e2567–79.

85. Min KB, Min JY. Urinary phthalate metabolites and the risk of low bone mineral density and osteoporosis in older women. J Clin Endocrinol Metab. 2014; 99:E1997–2003.

86. Bielanowicz A, Johnson RW, Goh H, Moody SC, Poulton IJ, Croce N, et al. Prepubertal di-n-butyl phthalate exposure alters sertoli and leydig cell function and lowers bone density in adult male mice. Endocrinology. 2016; 157:2595–603.

87. Chiu CY, Sun SC, Chiang CK, Wang CC, Chan DC, Chen HJ, et al. Plasticizer di(2-ethylhexyl)phthalate interferes with osteoblastogenesis and adipogenesis in a mouse model. J Orthop Res. 2018; 36:1124–34.

88. Choi JI, Cho HH. Effects of di(2-ethylhexyl)phthalate on bone metabolism in ovariectomized mice. J Bone Metab. 2019; 26:169–77.

89. Hwang YH, Son YJ, Paik MJ, Yee ST. Effects of diisononyl phthalate on osteopenia in intact mice. Toxicol Appl Pharmacol. 2017; 334:120–8.

90. Sabbieti MG, Agas D, Santoni G, Materazzi S, Menghi G, Marchetti L. Involvement of p53 in phthalate effects on mouse and rat osteoblasts. J Cell Biochem. 2009; 107:316–27.

91. Ferguson KK, Loch-Caruso R, Meeker JD. Exploration of oxidative stress and inflammatory markers in relation to urinary phthalate metabolites: NHANES 1999-2006. Environ Sci Technol. 2012; 46:477–85.

92. Ferguson KK, McElrath TF, Chen YH, Mukherjee B, Meeker JD. Urinary phthalate metabolites and biomarkers of oxidative stress in pregnant women: a repeated measures analysis. Environ Health Perspect. 2015; 123:210–6.

93. Johns LE, Ferguson KK, Meeker JD. Relationships between urinary phthalate metabolite and bisphenol a concentrations and vitamin D levels in U.S. adults: National Health and Nutrition Examination Survey (NHANES), 2005-2010. J Clin Endocrinol Metab. 2016; 101:4062–9.

94. Johns LE, Ferguson KK, Cantonwine DE, McElrath TF, Mukherjee B, Meeker JD. Urinary BPA and phthalate metabolite concentrations and plasma vitamin D levels in pregnant women: a repeated measures analysis. Environ Health Perspect. 2017; 125:087026.

95. Van den Berg M, Birnbaum LS, Denison M, De Vito M, Farland W, Feeley M, et al. The 2005 World Health Organization reevaluation of human and Mammalian toxic equivalency factors for dioxins and dioxin-like compounds. Toxicol Sci. 2006; 93:223–41.

96. Cripps DJ, Peters HA, Gocmen A, Dogramici I. Porphyria turcica due to hexachlorobenzene: a 20 to 30 year follow-up study on 204 patients. Br J Dermatol. 1984; 111:413–22.

97. Jones KC, de Voogt P. Persistent organic pollutants (POPs): state of the science. Environ Pollut. 1999; 100:209–21.

98. Tuomisto J. Are dioxins a health problem in Finland? Duodecim. 2001; 117:245–6.

99. Fukushi J, Tokunaga S, Nakashima Y, Motomura G, Mitoma C, Uchi H, et al. Effects of dioxin-related compounds on bone mineral density in patients affected by the Yusho incident. Chemosphere. 2016; 145:25–33.

100. Todaka T, Hori T, Hirakawa H, Kajiwara J, Yasutake D, Onozuka D, et al. Concentrations of polychlorinated biphenyls in blood of Yusho patients over 35 years after the incident. Chemosphere. 2009; 74:902–9.

101. Akamine A, Hashiguchi I, Maeda K, Hara Y, Chinjiu N, Iwamoto Y, et al. Prevalence of periodontal disease in patients with yusho. Fukuoka Igaku Zasshi. 1985; 76:248–52.

102. Shimizu K, Nakata S, Murakami T, Tamari K, Takahama Y, Akamine A, et al. Long-term occlusal guidance of a severely intoxicated patient with yusho (PCB poisoning): a case report. Am J Orthod Dentofacial Orthop. 1992; 101:393–402.

103. Eskenazi B, Warner M, Sirtori M, Fuerst T, Rauch SA, Brambilla P, et al. Serum dioxin concentrations and bone density and structure in the Seveso Women’s Health Study. Environ Health Perspect. 2014; 122:51–7.

104. Paunescu AC, Dewailly E, Dodin S, Nieboer E, Ayotte P. Dioxin-like compounds and bone quality in Cree women of Eastern James Bay (Canada): a cross-sectional study. Environ Health. 2013; 12:54.

105. TenHave-Opbroek AA, Shi XB, Gumerlock PH. 3-Methylcholanthrene triggers the differentiation of alveolar tumor cells from canine bronchial basal cells and an altered p53 gene promotes their clonal expansion. Carcinogenesis. 2000; 21:1477–84.

106. Naruse M, Ishihara Y, Miyagawa-Tomita S, Koyama A, Hagiwara H. 3-Methylcholanthrene, which binds to the arylhydrocarbon receptor, inhibits proliferation and differentiation of osteoblasts in vitro and ossification in vivo. Endocrinology. 2002; 143:3575–81.

107. Naruse M, Otsuka E, Naruse M, Ishihara Y, Miyagawa-Tomita S, Hagiwara H. Inhibition of osteoclast formation by 3-methylcholanthrene, a ligand for arylhydrocarbon receptor: suppression of osteoclast differentiation factor in osteogenic cells. Biochem Pharmacol. 2004; 67:119–27.

108. Monnouchi S, Maeda H, Yuda A, Serita S, Wada N, Tomokiyo A, et al. Benzo[a]pyrene/aryl hydrocarbon receptor signaling inhibits osteoblastic differentiation and collagen synthesis of human periodontal ligament cells. J Periodontal Res. 2016; 51:779–88.

109. Tsai KS, Yang RS, Liu SH. Benzo[a]pyrene regulates osteoblast proliferation through an estrogen receptor-related cyclooxygenase-2 pathway. Chem Res Toxicol. 2004; 17:679–84.

110. Voronov I, Li K, Tenenbaum HC, Manolson MF. Benzo[a] pyrene inhibits osteoclastogenesis by affecting RANKL-induced activation of NF-kappaB. Biochem Pharmacol. 2008; 75:2034–44.

111. Kung MH, Yukata K, O’Keefe RJ, Zuscik MJ. Aryl hydrocarbon receptor-mediated impairment of chondrogenesis and fracture healing by cigarette smoke and benzo(a)pyrene. J Cell Physiol. 2012; 227:1062–70.

112. Lind PM, Larsson S, Oxlund H, Hakansson H, Nyberg K, Eklund T, et al. Change of bone tissue composition and impaired bone strength in rats exposed to 3,3’,4,4’,5-pentachlorobiphenyl (PCB126). Toxicology. 2000; 150:41–51.

113. Alvarez-Lloret P, Lind PM, Nyberg I, Orberg J, Rodriguez-Navarro AB. Effects of 3,3’,4,4’,5-pentachlorobiphenyl (PCB126) on vertebral bone mineralization and on thyroxin and vitamin D levels in Sprague-Dawley rats. Toxicol Lett. 2009; 187:63–8.

114. Den Hond E, Roels HA, Hoppenbrouwers K, Nawrot T, Thijs L, Vandermeulen C, et al. Sexual maturation in relation to polychlorinated aromatic hydrocarbons: Sharpe and Skakkebaek’s hypothesis revisited. Environ Health Perspect. 2002; 110:771–6.